Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Study of Cladribine in Active SPMS
NCT04550455Phase 4Recruiting
- Sponsor
- Keith Edwards
- Start
- Sep 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in secondary-progressive multiple sclerosis (SPMS), sponsored by Keith Edwards. Primary endpoints: No Evidence of Disease Activity-4 at 96 weeks and Serum/CSF Neurofilament Light Chain at 48 weeks. Started Sep 2020; status: recruiting.
02
Drugs
cladribine
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT04550455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550455.